PFOA Risk Assessment and Cancer Toxicity

1. Methodology Overview

RoseyFields conducts PFOA risk assessments using the following methodology: we identify the exposure pathway and population relevant to the scenario under evaluation — most commonly general population drinking water ingestion, PFOA’s primary regulatory and practical exposure pathway of concern; we reconstruct or adopt exposure estimates using standard default or site-specific intake assumptions; we calculate a non-cancer hazard quotient (HQ) against the oral reference dose (RfD) and an excess lifetime cancer risk against the oral cancer slope factor (CSF); and we compare the resulting estimates against both the applicable regulatory standard (the enforceable Maximum Contaminant Level, or MCL) and standard risk-management benchmarks (HQ = 1; excess cancer risk in the 10⁻⁴ to 10⁻⁶ range). The summary below documents this exposure assessment and risk characterization approach in detail and explains how RoseyFields applies it in practice.

2. Endpoints Used for Risk Estimation

Non-cancer risk for PFOA is evaluated using a single overall RfD of 3 × 10⁻⁸ mg/kg-day, applicable to both acute and chronic exposure scenarios (see RoseyFields’ companion PFOA Toxicology & Hazard Characterization page for full derivation). This is a meaningful structural difference from TCE, PCE, and 1,4-dioxane, each of which requires separate acute and chronic non-cancer reference values and, for PCE and 1,4-dioxane, a margin-of-exposure (MOE) framework rather than a direct RfD/HQ comparison. Cancer risk for PFOA is evaluated using a single oral cancer slope factor of 0.0293 per ng/kg-day, anchored in human renal cell carcinoma data, applicable to chronic (lifetime-averaged) exposure only.

3. Risk Characterization Methodology

Non-Cancer Risk: Hazard Quotient (HQ)

Non-cancer risk is expressed as a hazard quotient, the ratio of estimated dose to the RfD:

HQ = Estimated Dose (mg/kg-day) ÷ RfD (3 × 10⁻⁸ mg/kg-day)

An HQ at or below 1 indicates the exposure is not expected to result in the adverse effects underlying the RfD (decreased vaccine antibody response, decreased birth weight, and increased total cholesterol) with an adequate margin of safety; an HQ above 1 indicates potential concern warranting further evaluation. Because the RfD is designed to be protective of both short-term and chronic exposure, RoseyFields applies the same HQ framework regardless of exposure duration, unlike its approach for TCE, PCE, and 1,4-dioxane.

Cancer Risk: Excess Lifetime Cancer Risk

Cancer risk is expressed as the incremental (excess) probability of developing cancer over a lifetime as a result of chronic exposure:

Excess Cancer Risk = Lifetime Average Daily Dose (ng/kg-day) × CSF (0.0293 per ng/kg-day)

Consistent with standard EPA practice, RoseyFields treats an excess lifetime cancer risk in the range of 1 × 10⁻⁴ to 1 × 10⁻⁶ as the range most regulatory frameworks use to characterize acceptable risk from a single contaminant, while noting that EPA’s own health-based goal for PFOA (the Maximum Contaminant Level Goal, or MCLG) is zero — reflecting EPA’s conclusion that there is no level of PFOA exposure without some risk of a health impact, given its classification as Likely to Be Carcinogenic to Humans.

Dose Reconstruction for Drinking Water Exposure

For the drinking-water pathway, dose is estimated as:

Dose (mg/kg-day) = Water Concentration (mg/L) × Drinking Water Intake Rate (L/kg-day)

RoseyFields uses population- and lifestage-specific drinking water intake rates from EPA’s Exposure Factors Handbook rather than a single default value wherever the exposed population is known, given that intake rate per unit body weight varies substantially across lifestages (infants and children have higher water intake relative to body weight than adults) and given that two of the RfD’s three co-critical effects are developmental, making children and formula-fed infants a particularly relevant population for this pathway specifically.

4. Regulatory Benchmark: The PFOA Drinking Water Standard

EPA’s 2024 PFAS National Primary Drinking Water Regulation (NPDWR) set a Maximum Contaminant Level Goal (MCLG) of zero for PFOA — the policy-driven, non-enforceable health-based goal EPA sets at zero whenever a contaminant has an identified cancer risk with no safe threshold — and an enforceable Maximum Contaminant Level (MCL) of 4.0 parts per trillion (ng/L), representing the level EPA determined to be as close to the MCLG as is feasible given current analytical detection capability, treatment technology, and cost. As of this page’s date, the 4.0 ppt MCL remains in effect; EPA proposed in May 2026 to retain the PFOA and PFOS MCLs unchanged while extending water systems’ compliance deadline from 2029 to 2031 (a proposal open for comment through July 20, 2026), while separately proposing to rescind the MCLs previously set for three other PFAS compounds. RoseyFields treats the MCL as the primary regulatory benchmark for PFOA drinking water risk assessment, while calculating HQ and excess cancer risk independently, since — as demonstrated in Section 5 — compliance with the MCL does not by itself guarantee an HQ at or below 1 or a cancer risk within the commonly used acceptable range.

5. Illustrative Risk Calculation

The following example illustrates RoseyFields’ standard methodology at three water concentrations: the current enforceable MCL (4.0 ppt), a concentration at the low end of the range EPA’s own assessment describes as representative of general population drinking water detections (approximately 2 ppt), and a concentration one order of magnitude below the MCL (0.4 ppt), using a default adult intake rate of 0.025 L/kg-day (approximating 2 L/day for an 80 kg adult) purely for illustration; site- or population-specific intake assumptions should be substituted for an actual assessment.

Under these default assumptions, the HQ does not fall to or below 1 until the water concentration drops to roughly one order of magnitude below the current enforceable MCL, and excess cancer risk remains above the upper end of the commonly used 10⁻⁴ to 10⁻⁶ acceptable range even at that lower concentration. This pattern — in which the enforceable standard itself corresponds to risk estimates above conventional risk-management benchmarks — is a direct consequence of EPA setting the MCL based on feasibility (detection and treatment capability) rather than purely on the health-based MCLG of zero, and is the single most important practical takeaway RoseyFields communicates to clients evaluating PFOA-impacted drinking water: regulatory compliance and health-protective exposure are not the same threshold for this chemical.

6. Interpreting PFOA Risk Estimates

• MCL compliance is not equivalent to an acceptable risk finding: as shown in Section 5, exposure at the current enforceable MCL corresponds to a non-cancer HQ above 1 and an excess cancer risk well above the commonly used acceptable range under standard default assumptions — RoseyFields treats this as essential context to convey alongside any statement that a water supply “meets” or “is below” the federal PFOA standard.
• A single RfD applies across acute and chronic scenarios: because PFOA’s RfD is explicitly designed to be protective of both short-term and chronic exposure, RoseyFields does not need to determine exposure duration before selecting a non-cancer benchmark — unlike TCE, PCE, and 1,4-dioxane, where the acute/chronic distinction changes both the reference value and the benchmark used.
• Lifestage-specific intake matters more for PFOA than for the volatile organic solvents in RoseyFields’ other pages: because two of the three co-critical RfD effects are developmental, and because infants and children have substantially higher water intake per unit body weight than adults, a default adult-only exposure calculation will generally understate risk for these subpopulations specifically.
• Drinking water is rarely the only PFOA exposure pathway for a given individual: given PFOA’s multi-year elimination half-life, current serum concentration reflects an accumulation of past exposure from water, diet, consumer products, and other sources, not only the water concentration being currently measured — a single-pathway HQ or cancer risk calculation, as illustrated in Section 5, will generally understate total individual risk.
• Mixture and co-occurrence considerations: PFOA frequently co-occurs with other regulated PFAS (PFOS, PFHxS, PFNA, HFPO-DA) in the same water supply; a full risk characterization should apply EPA’s Hazard Index framework for co-occurring PFAS mixtures rather than evaluating PFOA in isolation where other PFAS are also detected.

7. Application in RoseyFields Risk Assessments

For a given site- or client-specific PFOA risk assessment, RoseyFields follows this sequence:

• 1. Obtain or estimate the PFOA concentration in the relevant exposure medium (typically drinking water) using analytical methods capable of detecting PFOA at or below the 4.0 ppt MCL.
• 2. Apply population- and lifestage-specific exposure factors (drinking water intake rate, body weight) rather than a generic adult default, particularly where infants, children, or pregnant women are part of the exposed population.
• 3. Calculate both the non-cancer HQ (against the RfD, applicable to both acute and chronic scenarios) and the excess lifetime cancer risk (against the CSF, for chronic exposure only), and compare both to conventional risk-management benchmarks independently of MCL compliance status.
• 4. Where other PFAS co-occur with PFOA in the same medium, apply EPA’s Hazard Index mixture framework rather than relying on the PFOA-only HQ and cancer risk calculated here, and confirm the current federal MCL status for each co-occurring compound given the active 2026 rulemaking.
• 5. Report the numerical risk estimates alongside the specific finding that MCL compliance does not, on its own, correspond to an HQ at or below 1 or a cancer risk within the commonly used acceptable range under standard exposure assumptions — ensuring clients do not conflate regulatory compliance with a health-protective outcome for this chemical.

8. Conclusion

PFOA’s risk characterization differs structurally from RoseyFields’ TCE, PCE, and 1,4-dioxane pages: a single RfD applies across acute and chronic exposure, drinking water is the dominant and most tractable exposure pathway for quantitative assessment, and the enforceable regulatory standard (the 4.0 ppt MCL) is explicitly a feasibility-based compromise rather than a purely health-protective threshold, with the underlying health-based goal (the MCLG) set at zero. RoseyFields’ illustrative calculations show that exposure at the current MCL corresponds to a non-cancer HQ modestly above 1 and an excess cancer risk substantially above conventional acceptable-risk benchmarks under standard default drinking water assumptions — meaning MCL compliance should not, by itself, be presented to clients as equivalent to a finding of acceptable health risk. RoseyFields applies the HQ and excess cancer risk framework described here, informed by lifestage-specific exposure reconstruction and awareness of co-occurring PFAS mixtures, to characterize PFOA risk for the populations and pathways relevant to each site-specific assessment.

Bibliography